Investors

This section of the website provides financial reports, investor presentations, information on key corporate transactions and much more.

We strive to be transparent, relevant and accurate in presenting our financial information, in order to inform our stakeholders of the company’s operations and financial position.

If you have any questions, please don’t hesitate to contact us at investors@c-rad.com
Svensk version här

Sign up to our newsletter to keep up to date with investor news

Five reasons to invest in C-RAD

  • Contributing to improved cancer care and ultimately saving human life
  • Several factors point towards surface tracking becoming standard of care – which will unleash a vast market potential for C-RAD with exponential revenue growth
  • C-RAD has a proven and recognized product
  • C-RAD has comprehensive market access with a direct sales force, distributors, and direct cooperation with OEM-vendors
  • C-RAD has a stable financial platform – profitable growth, debt free and +100 MSEK in cash
Learn more

Press releases

2022-06-21 12:15 Cecilia de Leeuw ny VD för C-RAD från 21 december 2022 News Corporate Information Staff change Swedish Regulatory MAR IR
2022-06-08 09:00 ESTRO-ACROP released guidelines on surface guided radiation therapy News Corporate Information Other Corporate Information English IR
2022-05-31 08:30 Förändring av antalet aktier och röster i C-RAD AB (publ) News Corporate Action Shares Issuance Swedish Regulatory LHFI IR
2022-05-06 12:00 Kommuniké från årsstämma i C-RAD den 6 maj 2022 News Corporate Information General meeting Report of the AGM Swedish Regulatory Listing Regulation IR
2022-05-06 08:30 2022 ÖPPNAR MED SOLID TILLVÄXT I ORDERINGÅNG News Swedish Regulatory MAR Report Interim Q1 IR
2022-05-06 08:30 2022 OPENS WITH SOLID GROWTH IN ORDER INTAKE News English Regulatory MAR Report Interim Q1 IR

Shares & stock

Please feel free to contact us regarding investments or other financial questions

If you have any questions, please don’t hesitate to contact us